银杏达莫联合瑞舒伐他汀治疗不稳定型心绞痛的临床疗效

Clinical Efficacy of Ginkgo Dipyidamolum Combined with Rosuvastatin in the Treatment of Unstable Angina Pectoris

目的：探讨银杏达莫联合瑞舒伐他汀对不稳定型心绞痛患者IL-6,C反应蛋白（CRP）及临床疗效的影响。方法：收集2013年3月~2014年3月于我院就诊或住院治疗的100例不稳定型心绞痛患者,随机分为实验组和对照组,每组50例。对照组患者给予瑞舒伐他汀治疗,实验组患者在对照组基础上给予银杏达莫注射液治疗。观察并比较两组患者治疗前后血清IL-6,CRP,心绞痛发作频率、持续时间、不良反应发生率以及患者的临床疗效进行检测并比较。结果：与治疗前相比,治疗后患者的血清IL-6、CRP、心绞痛发作频率以及持续时间水平均下降（P〈0.05）;与对照组相比,实验组患者的血清IL-6、CRP、心绞痛发作频率水平较低（P〈0.05）,持续时间较短（P〈0.05）,不良反应发生率较低（P〈0.05）,临床治疗的总有效率较高（P〈0.05）。结论：银杏达莫联合瑞舒伐他汀能够降低不稳定型心绞痛患者IL-6,CRP水平,患者临床疗效较好,对临床有指导意义。

Objective： To investigate the clinical efficacy of ginkgo dipyidamolum combined with rosuvastatin of atorvastatin on unstable angina pectoris patients and its effect on the serum level of IL-6, C-reactive protein. Methods： 100 patients with unstable angina were selected and randomly divided into experimental group and control group with 50 cases in each group. All patients were given the crown expansion, antiplatelet, anticoagulant therapy, and the patients in the control group received rosuvastatin simvastatin, while the patients in experimental group were given intravenous drip of ginkgo dipyidamolum on the basis of the control group. All the patients were treated for 4 consecutive weeks. After the end of treatment, the serum level of IL-6 and CRP, and the angina attack frequency and duration,and incidence of adverse reactions as well as the clinical efficacy of patients were detected and compared. Results： Compared with before treatment, the serum IL-6 and CRP level, the angina attack frequency and duration were decreased in both groups（P〈0.05）;Compared with the control group, the serum level of IL-6 and CRP, and the angina attack frequency were lower（P 〈 0.05） and the duration was shorter in the experimental group（P 〈 0.05）, the incidence of adverse reactions was low（P 〈 0.05）,and the clinical treatment of the total efficiency was higher in the experimental group with statistical significance compared with control group（P 〈 0.05）.Conclusions： Ginkgo dipyidamolum combined with rosuvastatin of atorvastatin can reduce the serum level of IL-6 and CRP in the patients with unstable angina pectoris patients, and has good clinical efficacy.